Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Starting Grant

Descrizione del progetto

Sfruttare le specie reattive dell’ossigeno nei vaccini contro il cancro

Le specie reattive dell’ossigeno (reactive oxygen species, ROS) sono molecole chimicamente reattive derivate dall’ossigeno. Hanno un doppio ruolo, contribuendo sia al danno che alla difesa. Nell’immunità, le ROS agiscono come allarmi molecolari che attivano le cellule immunitarie per individuare ed eliminare il cancro. Il plasma fisico può generare ROS e sta quindi emergendo come nuovo strumento terapeutico. L’esposizione al plasma induce stress ossidativo nelle cellule tumorali, alterando i loro marcatori di superficie e migliorando il riconoscimento immunitario. Oltre all’uccisione diretta, le ROS ossidano anche le biomolecole rilasciate dalle cellule morenti e amplificano l’attivazione immunitaria. Il progetto PriME, finanziato dal CER, mira a generare un vaccino terapeutico antitumorale basato su lisati di cellule tumorali ossidati dal plasma.

Obiettivo

Efficient anticancer immune effects are a prime medical discovery of this century. Molecular alarms drive such immune responses, signaling priming and effector cells to action. Several approaches are studied or clinically used to initiate or support such action. Yet, the perhaps evolutionary old and most conserved mechanism has been mostly off the map so far: reactive oxygen species (Physical-technical applications extend into medicine for diagnostics and also therapies, such as: cancer treatment. Tumor cells present various receptors on the cell surface, and immune cells can interact with these receptors to decide whether a cell should be eliminated or not. Therapies or other external influences can change the spectrum of the presented receptors and thus the interaction, aiming to stimulate an immune response. Once a tumor cell gets identified as harmful, an immune response is initiated to recruit cytotoxic T cells and other adaptive immune cells to reduce tumor growth. Physical plasmas are therapeutic and have antimicrobial efficacy and cancer-killing effects. Plasmas can be generated to operate at low temperatures, which enables them for medical applications, and produced reactive oxygen and nitrogen species (ROS) mainly induce biomedical effects. In tumor cells, plasma treatment leads to redox stress, followed by altered surface marker expression, which has immune-stimulating properties. However, ROS are not absent when the tumor cell dies, and further ROS-mediated mechanisms, such as oxidation of released biomolecules, continue. I hypothesize that immune-stimulatory properties of plasma are combinatory effects of molecular changes and biomolecule oxidation, suggesting that a standardized plasma treatment with maximized ROS, more precisely radical production, optimizes biomolecule oxidation and immunological consequences. My vision is to establish a novel approach to plasma-treated cancers by oxidizing cancer lysates with plasma for use as a therapeutic vaccine.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2025-STG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

LEIBNIZ-INSTITUT FUR PLASMAFORSCHUNG UND TECHNOLOGIE EV
Contributo netto dell'UE
€ 1 499 892,00
Indirizzo
FELIX HAUSDORFF STRASSE 2
17489 Greifswald
Germania
Regione
Mecklenburg-Vorpommern Mecklenburg-Vorpommern Vorpommern-Greifswald
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 1 499 892,00

Beneficiari (1)